Introduction
============

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat arthritis, menstrual, musculoskeletal and post-operative pain, as well as headache and fever. NSAIDs include acetylsalicylic acid (ASA), traditional NSAIDs (tNSAIDs) (eg, diclofenac, ibuprofen, indomethacin, and naproxen) and inhibitors of the COX-2 isoform of cyclo-oxygenase (referred to here as COX-2s, eg, celecoxib, lumiracoxib, etoricoxib, rofecoxib).

One cohort study found that about 25% of Canadians in 2001 were prescribed short-term NSAIDs (a rise of 28% over 1999 when COX-2s were first introduced), and about 4% were prescribed these agents long-term (defined in this study as ≥6 months);[@b1-dhps-1-047] this equates to approximately 6.2 million short-term users, and 1.0 million long-term users of NSAID therapy. However, this substantially underestimates the true magnitude of NSAID uses since it does not include use of over the counter NSAIDs. A US cohort study, reported the point prevalence of daily prescription NSAID use as 8.7% between 2002 and 2003 with 46% being COX-2s.[@b2-dhps-1-047] Low-dose ASA is extensively used for cardiovascular risk reduction.

There are increasing concerns over the risks of gastrointestinal and cardiovascular adverse events with these medications. The increased risks of upper gastrointestinal ulcers and complications with tNSAIDs and ASA are well documented,[@b3-dhps-1-047]--[@b7-dhps-1-047] and while the risks are reduced by about 50% with COX-2s, they continue to be important since this risk is not reduced to baseline.[@b8-dhps-1-047]--[@b10-dhps-1-047] Furthermore with the introduction of COX-2s in the late 1990, overall NSAID prescriptions rose with COX-2s overtaking tNSAIDs suggesting that individuals not previously on NSAIDs were being prescribed COX-2s. Over the same time frame, there was a 75.9% increase in the rate of non-fatal digestive perforations and hemorrhages in the presence of NSAIDs. Moreover, the benefits of COX-2s are attenuated when COX-2s are co-prescribed with ASA[@b10-dhps-1-047] although to a lesser extent than when tNSAIDs are co-prescribed with ASA. In addition, extensive data associate COX-2s and non-naproxen tNSAIDs with an increased risk of cardiovascular events,[@b11-dhps-1-047],[@b12-dhps-1-047] which has led regulatory authorities to introduce warning statements and advisories Additionally, the COX-2s, rofecoxib, valdecoxib, and lumiracoxib have been withdrawn from the market because of cardiovascular, cutaneous, and hepatic adverse events respectively.[@b1-dhps-1-047],[@b2-dhps-1-047],[@b13-dhps-1-047]--[@b15-dhps-1-047] Health Canada and the Food and Drug Administration (FDA) require the product information for tNSAIDs and COX-2s to include a warning of the increased incidence of cardiovascular (eg, heart attack, stroke) and gastrointestinal (eg, ulcer, bleeding) adverse events, as well as recommendations to limit use of the drug to the lowest effective dose for the shortest possible duration of treatment.[@b2-dhps-1-047],[@b15-dhps-1-047]

The purpose of this study was to systematically review the literature on interventions to prevent tNSAID related upper gastrointestinal (GI) toxicity, and on the GI safety of COX-2s.

Methods
=======

This review was conducted in accordance with the methods of the Cochrane Collaboration.[@b16-dhps-1-047]

Literature search strategy
--------------------------

The search strategy and methods have been previously described elsewhere. These were updated to May 2009.[@b10-dhps-1-047],[@b17-dhps-1-047]

### Inclusion criteria

#### Types of studies

RCTs of COX-2s (celecoxib \[Celebrex^®^\], rofecoxib \[Vioxx^®^\], etoricoxib \[Arcoxia^®^\], valdecoxib \[Bextra^®^\], lumi-racoxib \[Prexige^®^\]) were considered eligible for inclusion if the upper GI toxicity of these agents was compared to that of a non-selective NSAID or to placebo. RCTs of prostaglandin analogues (misoprostol), H~2~-receptor antagonists (H2RA), and proton pump inhibitors (PPI) in the prevention of NSAID-induced upper GI toxicity were also considered if these agents were used alongside an NSAID compared to an NSAID alone. Further the RCTs had to meet the following additional criteria.

Participants were 18 years or older and had osteoarthritis, rheumatoid arthritis or another arthritic condition; NSAID exposure was 4 weeks or longer (chronic NSAID exposure); the proportion of patients with endoscopic ulcers, significant clinical GI events (eg, perforation, obstruction, bleeding, symptomatic ulcers), and/or symptom based clinical events (adverse GI symptoms, withdrawals due to GI symptoms) could be determined; endoscopic ulcers were defined as being at least 3 mm in diameter or could be distinguished from erosions based on the authors' descriptions; and it was noted whether endoscopy was performed based on symptoms or as part of a protocol.

#### Types of interventions

The interventions included the following COX-2s: celecoxib (Celebrex^®^), rofecoxib (Vioxx^®^), etoricoxib (Arcoxia^®^), valdecoxib (Bextra^®^), lumiracoxib (Prexige^®^). For this review, low-dose COX-2s were defined as celecoxib 200 mg bid or less, rofecoxib 25 mg daily or less, etoricoxib 60 mg daily or less, valdecoxib 10 mg daily or less, and lumiracoxib 100 to 200 mg. High-dose COX-2s were defined as celecoxib 400 mg bid, rofecoxib 50 mg daily, etoricoxib 90 mg daily or more, valdecoxib 20 mg daily or more, and lumiracoxib 400 mg or more. For prophylaxis against tNSAID induced upper GI toxicity we included: the prostaglandin antagonist misoprostol (Cytotec^®^) (low dose 400 μg/day, intermediate dose 600 μg/day; high dose 800 μg/day); the PPIs omeprazole, esomeprazole, pantoprazole, and lansoprazole (Losec^®^, Nexium^®^, Pantoloc^®^, Prevacid^®^, respectively); and the H2RAs cimetadine, ranitidine, nizatidine, and famotidine (Tagamet^®^, Zantac^®^, Axid^®^, and Pepcid^®^, respectively). Double doses of H2RAs were defined as a dose equivalent to or greater than 300 mg of ranitidine twice daily, and standard dose of PPIs were considered the equivalent of 20 mg of omeprazole once daily.

#### Types of outcome measures

The primary outcomes were: endoscopically detected ulcer in endoscopy trials; and clinical GI events. Clinically important adverse events were categorized in two ways: 1) strict ulcer complications, which are referred to as "POB" (for perforation, obstruction or bleeding), and 2) ulcer complications and/or ulcer-related symptoms that lead to the identification of an ulcer (so called symptomatic ulcer), which are referred to as "PUB" (for perforation, obstruction, bleeding or the presence of a symptomatic ulcer). Efficacy/tolerability trials were defined as studies that focused on clinical efficacy or effectiveness of COX-2s but also reported on adverse symptoms or other clinical adverse events. Secondary outcomes were: adverse GI symptoms (dyspepsia, nausea, abdominal pain, or diarrhea); and treatment withdrawals due to GI symptoms.

Quality assessment
------------------

All RCTs were scored for quality by 2 independent reviewers using the Jadad scale.[@b18-dhps-1-047] The quality of allocation concealment was also assessed.[@b19-dhps-1-047] Differences were resolved by consensus.

Statistical analysis
--------------------

Data were analyzed using Review Manager (RevMan) version 5.0. Endoscopic, clinical and symptom-based outcomes were analyzed separately. The primary analyses were expressed as relative risks using a fixed effects model. A random-effects model was used to combine "heterogeneous trials" only if it was clinically and statistically appropriate. The absolute risk reduction (ARR) was calculated for appropriate clinical endpoints.

Subgroup analyses
-----------------

Studies were grouped by interventions (eg, COX-2s vs tNSAIDs, and COX-2s vs placebo), dosage (low-dose and high-dose), and duration of therapy. Additionally, within each of the three main outcome analyses (endoscopic ulcer, clinical ulcer, and symptoms), studies were analyzed as all COX-2s vs all tNSAIDs, individual COX-2s vs all comparator tNSAIDs, individual tNSAIDs vs all comparator COX-2s, and individual COX-2s vs individual tNSAIDs.

Heterogeneity
-------------

Sources for clinical and statistical heterogeneity were sought prior to statistical analyses. Logical analyses subgroups were created (see above) to allow for more homogeneous analyses groups. Heterogeneity was tested using the I^2^ statistic and a chi-square test. An I^2^ \> 50% or a chi-square p value of less than 0.10 is considered to be evidence of statistical heterogeneity.[@b20-dhps-1-047]

Sensitivity analyses
--------------------

In addition to the published reports, unique studies were identified from the FDA web site, and in the form of published "combined analyses" studies. The latter studies combined published and unpublished primary patient data from the endoscopic studies, as well as the safety and tolerability studies to allow sample sizes large enough to comment on clinical ulcer complications. We carefully examined these studies by their ID number, their sample size, patient demographics and list of authors and cross referenced with the FDA web site in order to ensure that their use in the ulcer complication analyses would not create duplication of individual patient data. Sensitivity analyses were conducted removing or adding FDA studies, and the combined analyses studies. Additionally, sensitivity analyses were used to assess the impact of supplemental FDA data on published study results when available (eg, CLASS study). Sensitivity analysis was also performed removing studies with quality scores of 2 or less.

Results
=======

Part I -- tNSAID prophylaxis
----------------------------

Of a total of 1205 references with 256 being potentially relevant, 39 RCTs met the inclusion criteria: 23 misoprostol trials (includes 6 head to head studies); 12 H2RA (9 standard dose, 3 double dose, 1 head to head); and 9 PPI trials (6 direct, 5 head to head). Some studies considered more than one active intervention. [Table 1](#t1-dhps-1-047){ref-type="table"} summarizes the characteristics of the included studies. Effects of interventions are summarized below.

### Misoprostol

We found 23 studies that assessed the long term effect of misoprostol on the prevention of tNSAID ulcers.[@b14-dhps-1-047],[@b21-dhps-1-047]--[@b42-dhps-1-047]

### Endoscopic ulcers

Eleven studies with 3,641patients compared the incidence of endoscopic ulcers, after at least 3 months, of misoprostol to that of placebo.[@b21-dhps-1-047],[@b22-dhps-1-047],[@b25-dhps-1-047],[@b29-dhps-1-047]--[@b33-dhps-1-047],[@b36-dhps-1-047],[@b38-dhps-1-047],[@b42-dhps-1-047] The cumulative incidence of endoscopic gastric and duodenal ulcers with placebo were 15% and 6% respectively. Misoprostol (any dose combined) significantly reduced the relative risk of gastric ulcer and duodenal ulcers by 74% relative risk \[RR\] 0.26; 95% confidence interval \[CI\] 0.17 to 0.39, random effects), and 58% (RR 0.42; 95% CI 0.22 to 0.81, random effects). These relative risks correspond to a 12.0%, and 3% absolute risk reductions for gastric and duodenal ulcers respectively. The observed heterogeneity in these estimates was due to inclusion of all misoprostol doses in the analyses. Analysis of the misoprostol studies stratified by dose eliminated this heterogeneity.

### Analysis by dose

All the studied doses of misoprostol significantly reduced the risk of endoscopic ulcers, and a dose response relationship was demonstrated for endoscopic gastric ulcers. Six studies with 2,461 patients used misoprostol 400 μg.[@b22-dhps-1-047],[@b25-dhps-1-047],[@b30-dhps-1-047],[@b33-dhps-1-047],[@b36-dhps-1-047],[@b42-dhps-1-047] 1 study with 928 patients used 600 μg daily,[@b36-dhps-1-047] and 7 with 2,423 patients used 800 μg daily.[@b21-dhps-1-047],[@b29-dhps-1-047]--[@b32-dhps-1-047],[@b36-dhps-1-047],[@b38-dhps-1-047] Misoprostol 800 μg daily was associated with the lowest risk (RR 0.17; 95% CI 0.11 to 0.24) of endoscopic gastric ulcers when compared to placebo, whereas misoprostol 400 ug daily was associated with a relative risk of 0.42 (95% CI 0.28 to 0.67, random effects model for heterogeneity) ([Figure 1](#f1-dhps-1-047){ref-type="fig"}). This difference between high- and low-dose misoprostol reached statistical significance (*P*0.0055). The intermediate misoprostol dose (600 μg daily) was not statistically different from either the low or high dose. The pooled relative risk reduction of 78% (4.7% absolute risk difference, RR 0.21; 95% CI 0.09 to 0.49) for duodenal ulcers with misoprostol 800 μg daily was not statistically different from those of the lower daily misoprostol dosages.

### Studies including data with less than 3 months tNSAID exposure

Eight studies, with 2,206 patients, assessed the rates of endoscopic ulcers with misoprostol compared to placebo at 1 to 1.5 months.[@b14-dhps-1-047],[@b23-dhps-1-047],[@b24-dhps-1-047],[@b26-dhps-1-047],[@b28-dhps-1-047],[@b29-dhps-1-047],[@b34-dhps-1-047],[@b39-dhps-1-047] The pooling of these studies revealed an 81% relative risk reduction of gastric ulcers with misoprostol (RR 0.17; 95% CI 0.09 to 0.31) and an 72% relative risk reduction of duodenal ulcers (RR 0.28; 95% CI 0.14 to 0.56).

One study compared misoprostol to a newer cytoprotective agent, dosmafate, for tNSAID prophylaxis and found no statistically significant difference in ulcer rates between the two agents.[@b27-dhps-1-047]

### Clinical ulcers

Only 1 RCT, the MUCOSA trial, evaluated the efficacy of misoprostol prophylaxis against clinically important TNSAID induced ulcer complications as the powered primary endpoint. In this study, of 8,843 patients studied over 6 months, the overall GI event incidence was about 1.5% per year.[@b40-dhps-1-047] Misoprostol 800 μg/day was associated with a statistically significant 40% risk reduction (odds ratio0.598; 95% CI 0.364 to 0.982) in combined GI events (*P*0.049), representing a risk difference of 0.38% (from 0.95% to 0.57%).

### Adverse effects

Misoprostol was associated with a small but statistically significant 1.6 fold excess risk of drop out due to drug induced side effects, and an excess risk of drop-outs due to nausea (RR 1.30; 95% CI 1.08 to 1.55), diarrhea (RR 2.36; 95% CI 2.01 to 2.77), and abdominal pain (RR 1.36; 95% CI 1.20 to 1.55). In the MUCOSA trial, 732 out of 4,404 patients on misoprostol experienced diarrhea or abdominal pain, compared to 399 out of 4,439 on placebo for a relative risk of 1.82 associated with misoprostol (*P* \< 0.001). Overall 27% of patients on misoprostol experienced one or more side effects.[@b40-dhps-1-047]

When analyzed by dose, only misoprostol 800 μg daily showed a statistically significant excess risk of drop-outs due to diarrhea (RR 2.45; 95% CI 2.09 to 2.88), and abdominal pain (RR 1.38; 95% CI 1.17 to 1.63). Both misoprostol doses were associated with a statistically significant risk of diarrhea. However, the risk of diarrhea with 800 μg/day (RR 3.25; 95% CI 2.60 to 4.06) was significantly higher than that seen with 400 μg/day (RR 1.81 95% CI 1.52 to 2.16) (*P*0.0012). The results for overall dropouts due to symptoms analyzed by dose are shown in [Figure 2](#f2-dhps-1-047){ref-type="fig"}.

H2RAs
-----

Seven trials with over 900 patients assessed the effect of standard dose H2RAs on the prevention of endoscopic tNSAID ulcers at 1 month,[@b43-dhps-1-047]--[@b48-dhps-1-047] and 5 trials with 1,005 patients assessed these outcomes at 3 months or longer.[@b44-dhps-1-047],[@b47-dhps-1-047],[@b49-dhps-1-047]--[@b51-dhps-1-047] Standard dose H2RAs are effective at reducing the risk of duodenal ulcers (RR 0.24; 95% CI 0.10 to 0.57, and RR 0.36; 95% CI 0.18 to 0.74 at 1 and 3 or more months respectively), but not of gastric ulcers (NS). One study did not have a placebo comparator and was not included in the pooled estimate.[@b51-dhps-1-047]

Three RCTs with 298 patients assessed the efficacy of double dose H2RA for the prevention of tNSAID induced upper GI toxicity.[@b47-dhps-1-047],[@b52-dhps-1-047],[@b53-dhps-1-047] Double-dose H2RAs when compared to placebo were associated with a statistically significant reduction in the risk of both duodenal (RR 0.26; 95% CI 0.11 to 0.65) and gastric ulcers (RR 0.44; 95% CI 026 to 0.74). This 56% relative risk reduction in gastric ulcer corresponds to a 12% absolute risk difference (from 23.1% to 11.3%) ([Figures 3](#f3-dhps-1-047){ref-type="fig"} and [4](#f4-dhps-1-047){ref-type="fig"}). Analysis of the secondary prophylaxis studies alone yielded similar results.

### Symptoms

H2RA, in standard or double doses, were not associated with an excess risk of total drop-outs, dropouts due to side effects, or symptoms compared to placebo. However, high-dose H2RAs significantly reduced symptoms of abdominal pain when compared to placebo (RR 0.57, 95% CI 0.33 to 0.98).

PPIs
----

Six RCTs with 1,259 patients assessed the effect of PPIs on the prevention of NSAID-induced upper GI toxicity.[@b32-dhps-1-047],[@b33-dhps-1-047],[@b54-dhps-1-047]--[@b57-dhps-1-047]

PPIs significantly reduced the risk of both endoscopic duodenal (RR 0.20; 95% CI 0.10 to 0.39) and gastric ulcers (RR 0.39; 95% CI 0.31 to 0.50) compared to placebo ([Figures 5](#f5-dhps-1-047){ref-type="fig"} and [6](#f6-dhps-1-047){ref-type="fig"}).[@b32-dhps-1-047],[@b33-dhps-1-047],[@b54-dhps-1-047]--[@b57-dhps-1-047] The results were similar for both primary and secondary prophylaxis trials.

### 

#### Symptoms

Four omeprazole trials used the same composite endpoints to define treatment success.[@b33-dhps-1-047],[@b55-dhps-1-047],[@b56-dhps-1-047],[@b58-dhps-1-047] In these trials omeprazole significantly reduced "dyspeptic symptoms" as defined by the authors. In the combined analysis, drop-outs overall (RR 0.89; 95% CI 0.62 to 1.29) and drop-outs due to side effects (RR 1.20; 95% CI 0.66 to 2.15) were not different from placebo.

Head to head comparisons of gastroprotective agents
---------------------------------------------------

### Misoprostol vs H2RAs

Two trials with 600 patients compared misoprostol (400 to 800 μg) to ranitidine 150 mg twice daily.[@b36-dhps-1-047],[@b41-dhps-1-047] Misoprostol appears superior to standard dose ranitidine for the prevention of tNSAID induced gastric ulcers (RR 0.12; 95% CI 0.03 to 0.51) but not for duodenal ulcers (RR 1.00; 95% CI 0.14 to 7.14).

### PPI vs H2RAS

Yeomans et al in a 12-week study of 425 patients, compared omeprazole 20 mg daily to ranitidine 150 mg twice daily for tNSAID prophylaxis (various tNSAIDs used).[@b58-dhps-1-047] In this study, omeprazole was superior to standard-dose ranitidine for the prevention of both gastric (RR 0.32; 95% CI 0.17 to 0.62) and duodenal ulcers (RR 0.11; 95% CI 0.01 to 0.89).

### PPI vs misoprostol

Four trials with a total of 1,478 patients[@b13-dhps-1-047],[@b32-dhps-1-047],[@b33-dhps-1-047],[@b35-dhps-1-047] compared a PPI to misoprostol. Two studies compared low-dose misoprostol (400 μg) daily to a standard-dose PPI[@b13-dhps-1-047],[@b33-dhps-1-047] while the Graham study compared high-dose misoprostol (800 μg) to lansoprazole 15 or 30 mg daily. PPIs are superior to misoprostol for the prevention of duodenal (RR 0.25; 95% CI 0.11 to 0.056), but not gastric (RR 1.61; 95% CI 0.88 to 3.06, random effects) or total gastroduodenal ulcers (RR 0.90; 95% CI 0.47 to 1.72, random effects).

Symptoms
--------

In the two head to head comparison of omeprazole and misoprostol,[@b32-dhps-1-047],[@b33-dhps-1-047] PPIs were associated with significantly less drop-outs overall (RR 0.71; 95% CI 0.52 to 0.97), as well as significantly less drop-outs due to side effects (RR 0.48; 09% CI 0.29 to 0.78). Compared to H2RA used for less than 2 months, misoprostol caused significantly more drop-outs due to abdominal pain (RR 3.00, 95% CI 1.11 to 8.14) and more symptoms of diarrhea (RR 2.03, 95% CI 1.38 to 2.99). There were no significant differences in drop-outs due to side effects (RR 1.90, 95% CI 0.77 to 4.67) or symptoms of abdominal pain or diarrhea between low-dose H2RAs and PPIs.

Part II -- COX-2 inhibitors
===========================

The search strategy identified 1,169 studies. Of these, 255 references were rated as potentially relevant and the full articles were retrieved. Sixty studies met the inclusion criteria, including 4 unique studies obtained from the new drug submission documents on the FDA web site.[@b59-dhps-1-047]--[@b63-dhps-1-047] An additional 5 "combined analyses studies" were identified by the search strategy and were included for the clinical ulcer complication endpoint ([Table 2](#t2-dhps-1-047){ref-type="table"}).[@b64-dhps-1-047]--[@b68-dhps-1-047]

Quality scores of the 60 included trials ranged between 4 to 5 in 47 and between 2 to 3 in 22 studies. Removal of quality score 2 studies did not influence overall results. The use of allocation concealment was implied in all of the included trials, but was adequately described in only 6 studies.

Endoscopic ulcers were the measured endpoints of 17 studies.[@b59-dhps-1-047]--[@b61-dhps-1-047],[@b63-dhps-1-047],[@b69-dhps-1-047]--[@b81-dhps-1-047] Eleven COX-2 studies,[@b78-dhps-1-047],[@b82-dhps-1-047]--[@b91-dhps-1-047] and 5 combined analyses[@b65-dhps-1-047]--[@b68-dhps-1-047],[@b92-dhps-1-047] reported on the outcome of clinical GI events (POBs or PUBs).

The remaining trials were either safety or tolerability studies or examined the clinical efficacy of COX-2s compared to tNSAIDS, but allowed for extraction of GI tolerability data.[@b62-dhps-1-047],[@b67-dhps-1-047],[@b88-dhps-1-047],[@b93-dhps-1-047]--[@b111-dhps-1-047] FDA study data are only presented as part of sensitivity analyses. Results specifically pertaining to meloxicam are not included herein.

Endoscopic ulcer trials
-----------------------

### CoX-2s vs non-selective NSAIDs

Seventeen studies with over 10,000 patients assessed the proportion of patients who developed endoscopic ulcers while taking a COX-2 compared to those taking a tNSAID.[@b59-dhps-1-047]--[@b61-dhps-1-047],[@b63-dhps-1-047],[@b69-dhps-1-047]--[@b79-dhps-1-047],[@b81-dhps-1-047] Seven studies assessed celecoxib,[@b59-dhps-1-047],[@b60-dhps-1-047],[@b69-dhps-1-047]--[@b71-dhps-1-047],[@b75-dhps-1-047],[@b81-dhps-1-047] 3 assessed rofecoxib,[@b72-dhps-1-047]--[@b74-dhps-1-047] 2 assessed etoricoxib,[@b78-dhps-1-047],[@b79-dhps-1-047] 5 that assessed valdecoxib,[@b61-dhps-1-047],[@b63-dhps-1-047],[@b76-dhps-1-047],[@b77-dhps-1-047],[@b80-dhps-1-047] and 2 assessed lumiracoxib.[@b75-dhps-1-047],[@b81-dhps-1-047] Some studies assessed more than one intervention.[@b75-dhps-1-047],[@b81-dhps-1-047]

### Endoscopically detected gastro-duodenal ulcers

Thirteen studies with a total of 7,839 patients showed a 74% relative risk reduction (RRR) in combined gastro-duodenal ulcers with COX-2s vs tNSAIDs (RR 0.26; 95% CI 0.23 to 0.30).[@b69-dhps-1-047]--[@b80-dhps-1-047],[@b112-dhps-1-047] This represented a 16% absolute risk reduction (ARR). Addition of the FDA studies did not significantly alter the results (RR 0.28; 95% CI 0.24 to 0.32). The results analyzed by the dose of COX-2s gave similar results. Results below are for "any dose" combined.

Eleven studies with a total of 6,726 patients compared the safety of a COX-2 to a comparator tNSAID for endoscopic gastric ulcers.[@b69-dhps-1-047]--[@b77-dhps-1-047],[@b80-dhps-1-047],[@b112-dhps-1-047] The use of a COX-2 in this setting was associated with a 79% RRR in gastric ulcers (RR 0.21; 95% CI 0.18 to 0.25) ([Figure 7](#f7-dhps-1-047){ref-type="fig"}). This represented a 14% ARR in gastric ulcers with the use of COX-2s compared with tNSAIDs. Addition of the FDA studies did not significantly alter the results (RR 0.26; 95% CI 0.22 to 0.30).

The same 11 studies also compared the proportions of duodenal ulcers that occurred while using a COX-2 vs a tNSAID.[@b69-dhps-1-047]--[@b77-dhps-1-047],[@b80-dhps-1-047],[@b112-dhps-1-047] Compared to using a tNSAID, the use of a COX-2 was associated with a 66% RRR in duodenal ulcers (RR 0.34; 95% CI 0.25 to 0.45) ([Figure 7](#f7-dhps-1-047){ref-type="fig"}). This represented a 3% ARR. Addition of the FDA studies did not significantly alter the results (RR 0.29; 95% CI 0.23 to 0.38) Keeping in mind that tNSAID related gastric ulcers were more commonly observed than duodenal ulcer, a trend was observed for greater RRR and ARR in gastric ulcers than for duodenal ulcers with COX-2s, compared to tNSAIDs (RR 0.21 vs 0.34, ARR of 14% vs 3%). This trend was consistent when celecoxib, rofecoxib and valdecoxib were analyzed separately. Analysis by duration The data presented above are for any dose and duration up to 6 months. Subgroup analysis of these studies on the basis of duration (1 to 3 months and 3 to 6 months) did not significantly alter the results.

### Analysis by COX-2

Analyses stratified by the individual COX-2s showed that each of the studied agents were safer than comparator tNSAIDs ([Figure 8](#f8-dhps-1-047){ref-type="fig"}).

#### Celecoxib

Five studies with a total of 2,439 patients compared celecoxib to non-selective NSAIDs, showing a 79% RRR in total gastro-duodenal ulcers (RR 0.21; 95% CI 0.16 to 0.28) with celecoxib.[@b69-dhps-1-047]--[@b71-dhps-1-047],[@b75-dhps-1-047],[@b112-dhps-1-047] Similar RRR were observed for gastric ulcers (RR 0.20; 95% CI 0.14 to 0.28) and duodenal ulcers alone (RR 0.29; 95% CI 0.18 to 0.47), as well as when the FDA studies were included (RR 0.26; 95% CI 0.21 to 0.32).

#### Rofecoxib

Three studies with a total of 1,526 patients compared rofecoxib to non-selective NSAIDs.[@b72-dhps-1-047]--[@b74-dhps-1-047] In this case, a 74% RRR was seen with rofecoxib (RR 0.26; 95% CI: 0.21 to 0.32). The results were similar when FDA studies were added to the analysis as well as when the analysis was done only for gastric ulcers (RR 0.20; 95% CI 0.15 to 0.26) and duodenal ulcers alone (RR 0.36; 95% CI 0.14 to 0.93, random effects).

#### Etoricoxib

Two studies, with a total of 900 patients compared etoricoxib to non-selective NSAIDs using the endpoint of endoscopic gastro-duodenal ulcers.[@b78-dhps-1-047],[@b79-dhps-1-047] These trials demonstrated a 64% RRR (RR 0.37; 95% CI 0.18 to 0.77, random effects) with etoricoxib.

#### Valdecoxib

Three studies compared valdecoxib to non-selective NSAIDs in 2,045 patients and demonstrated a 70% RRR in gastro-duodenal ulcers (RR 0.29; 95% CI 0.21 to 0.39) with valdecoxib.[@b76-dhps-1-047],[@b77-dhps-1-047],[@b80-dhps-1-047] Similar RRR were observed when the analysis was done for gastric ulcers (RR 0.24; 95% CI 0.18--0.37) and duodenal ulcers alone (RR 0.39; 95% CI 0.21 to 0.70), and when the FDA studies were included in the gastro-duodenal ulcers analysis (RR 0.30; 95% CI 0.24 to 0.39).

#### Lumiracoxib

Two studies with a total of 1,376 patients compared lumiracoxib to non-selective NSAIDs.[@b112-dhps-1-047],[@b113-dhps-1-047] Lumiracoxib was associated with a 74% RRR in gastro-duodenal ulcers (RR 0.26; 95% CI 0.18 to 0.39). Similar results were observed for gastric ulcers (RR 0.25; 95% CI 0.16 to 0.40) and duodenal ulcers (RR 0.20; 95% CI 0.09 to 0.43) when they were considered alone.

### Analysis by comparator NSAIDs

#### Naproxen

Five studies compared either celecoxib or valdecoxib to naproxen in 2,734 patients. These showed a 75% RRR in endoscopic gastro-duodenal ulcers in favor of the COX-2s (RR 0.25; 95% CI 0.20 to 0.32). Results were similar when the FDA studies were included in the analysis (RR 0.27; 95% CI: 0.22 to 0.32).[@b69-dhps-1-047],[@b71-dhps-1-047],[@b74-dhps-1-047],[@b79-dhps-1-047],[@b80-dhps-1-047]

#### Ibuprofen

Six studies which enrolled over 3,800 patients (2 rofecoxib,[@b72-dhps-1-047],[@b73-dhps-1-047] 1 etoricoxib,[@b78-dhps-1-047] 2 lumiracoxib,[@b112-dhps-1-047],[@b113-dhps-1-047] and 1 valdecoxib[@b76-dhps-1-047]) showed a 73% RRR in gastro-duodenal ulcers with COX-2s compared with ibuprofen (RR 0.27; 95% CI 0.23 to 0.32). Results were similar when the FDA studies were included in the analysis (RR 0.28; 95% CI 0.23 to 0.32).

#### Diclofenac

Three studies which enrolled a total of 1,596 patients demonstrated a 75% RRR in gastro-duodenal ulcers with COX-2s compared to diclofenac (RR 0.25; 95% CI 0.18 to 0.35). This effect was somewhat reduced when the FDA studies were included in the analysis (RR 0.36; 95% CI 0.27 to 0.47).[@b70-dhps-1-047],[@b76-dhps-1-047],[@b77-dhps-1-047]

Similar results were obtained when individual COX-2s were compared with the individual non-selective NSAIDs.

### COX-2s vs placebo

Eight studies with a total of 4,081 patients compared low- and high-dose COX-2s to placebo.[@b71-dhps-1-047]--[@b74-dhps-1-047],[@b76-dhps-1-047],[@b78-dhps-1-047]--[@b80-dhps-1-047] Low dose COX-2s appeared to demonstrate no greater risk of gastric or gastro-duodenal ulcers than placebo. However, high doses of COX-2s appeared to raise the relative risk of gastric (RR 1.22; 95% CI 0.83 to 1.80), duodenal (RR 1.29; 95% CI 0.63 to 2.66), and combined gastro-dudenal ulcers (RR 1.57; 95% CI 0.96 to 2.56, random effects), though these trends missed statistical significance. Clinical GI events COX-2s vs non-selective NSAIDs Nine studies with a total of 94,294 patients assessed the safety of COX-2s by using the clinically important endpoint of ulcer complication, POB.[@b65-dhps-1-047],[@b66-dhps-1-047],[@b68-dhps-1-047],[@b82-dhps-1-047],[@b83-dhps-1-047],[@b92-dhps-1-047],[@b114-dhps-1-047]--[@b116-dhps-1-047] Three of these trials studied celecoxib,[@b82-dhps-1-047],[@b92-dhps-1-047],[@b115-dhps-1-047] 2 studied rofecoxib,[@b66-dhps-1-047],[@b83-dhps-1-047] 2 trials evaluated etoracoxib,[@b68-dhps-1-047],[@b116-dhps-1-047] and 1 each evaluated valdecoxib[@b65-dhps-1-047] and lumiracoxib[@b114-dhps-1-047] separately. Overall, the use of these COX-2s was associated with a 57% RRR in POBs (RR, 0.43; 95% CI 0.28 to 0.67, random effects), compared with using tNSAIDs. Removal of the combined analyses studies had no influence on the result (RR 0.39; 0.29 to 0.53) and the inclusion of the FDA 12-month CLASS study data[@b117-dhps-1-047] did not alter the results (RR 0.42; 95% CI 0.33 to 0.54). The 60% RRR in these analyses represents an ARR of 0.4% ([Figure 9](#f9-dhps-1-047){ref-type="fig"}).

Fourteen studies compared COX-2s with tNSAIDs by using PUB as the study endpoint.[@b65-dhps-1-047],[@b66-dhps-1-047],[@b68-dhps-1-047],[@b78-dhps-1-047],[@b82-dhps-1-047],[@b83-dhps-1-047],[@b87-dhps-1-047]--[@b90-dhps-1-047],[@b92-dhps-1-047],[@b114-dhps-1-047]--[@b116-dhps-1-047] In this analysis, the use of a COX-2 was associated with a 57% RRR in PUBs (RR 0.43; 95% CI 0.34 to 0.55, random effects). Removal of the combined analyses studies eliminated the observed heterogeneity but had little effect on the point estimate (RR 0.49; 95% CI 0.41 to 0.58). Similarly, the use of the FDA CLASS data did not significantly alter the estimate (RR 0.42; 95% CI 0.33 to 0.53, random effects) ([Figure 10](#f10-dhps-1-047){ref-type="fig"}).

### Analyses stratified by cyclooxygenase-2s

#### Celecoxib

Four studies with 31,106 assessed the effect celecoxib vs non-selective NSAIDs on clinical GI events (POBs or PUBs).[@b82-dhps-1-047],[@b89-dhps-1-047],[@b92-dhps-1-047] Celecoxib use was associated with a 77% RRR in POBs (RR 0.23; 95% CI 0.07 to 0.76, random effects) and a 61% RRR in PUBs (RR 0.39; 95% CI 0.21 to 0.73, random effects). Removal of the combined analyses study[@b92-dhps-1-047] eliminated the heterogeneity observed in both the POB (RR 0.42; 95% CI 0.22 to 0.80) and PUBs (RR = 0.34; 95% CI 0.22 to 0.80) analyses. The use of the FDA 12-month CLASS data did not alter the RR estimates for POBs or PUBs significantly.

#### Rofecoxib

Four studies with 19,288 patients assessed the effect of rofecoxib vs non-selective NSAIDs on clinical GI events (POBs or PUBs).[@b66-dhps-1-047],[@b83-dhps-1-047],[@b88-dhps-1-047],[@b90-dhps-1-047] Rofecoxib use reduced the relative risk of POBs by 58% (RR 0.42; 95% CI 0.24 to 0.73) and the relative risk of PUBs by 56% (RR 0.44; 95% CI 0.34 to 0.58). Removal of the combined analysis study did not alter the point estimates.

#### Valdecoxib

One combined analysis study with 6,461 patients evaluated the effect of valdecoxib on POBs and PUBs.[@b65-dhps-1-047] Valdecoxib reduced the relative risk of POBs by 65% (RR 0.35; 95% CI 0.14 to 0.87) and the relative risk of PUBs by 77% (RR 0.23; 95% 0.15 to 0.36).

#### Etoricoxib

Four studies with 10,856 patients evaluated the effect of etoricoxib on POBs[@b68-dhps-1-047],[@b116-dhps-1-047] and PUBs.[@b78-dhps-1-047],[@b87-dhps-1-047] Etoricoxib demonstrated a nonsignificant trend in reducing the risk of POBs (RR 0.82; 95% CI 0.44 to 1.51, random effects), but it significantly reduced the RR of PUBs by 46% (RR 0.64; 95% CI 0.42 to 0.96).

#### Lumiracoxib

One study with 18,244 patients demonstrated a significant 64% RRR in POBs (RR 0.36; 95% CI 0.24 to 0.55) and a 44% RRR in PUBs (RR 0.56; CI 0.41 to 0.78) with the use of lumiracoxib, compared with using non-selective NSAIDs.[@b114-dhps-1-047]

### Analysis by comparator NSAIDs

In general COX-2s appeared to maintain their safety advantage regardless of the comparator non-selective NSAID. COX-2s were statistically superior to naproxen (RR 0.34; 95% CI 0.24 to 0.48), and ibuprofen (RR 0.46; 95% CI 0.30 to 0.71) for the POB endpoint. The data comparing COX-2s to diclofenac are predominately derived from 2 studies and heavily influenced by the CLASS trial data which showed no significant difference between celecoxib vs diclofenac.[@b82-dhps-1-047],[@b92-dhps-1-047] In the current analysis, celecoxib demonstrated a non-significant trend towards fewer POBs than diclofenac (RR 0.31; 95% CI 0.06 to 1.61) while a statistically significant 59% RRR in PUBs was observed (RR 0.41; 95% CI 0.30 to 0.55).

### COX-2s vs placebo

There are limited data, mostly derived from the combined analyses studies, comparing COX-2s with placebo for the clinical outcomes of POBs[@b65-dhps-1-047],[@b92-dhps-1-047] and PUBs.[@b65-dhps-1-047],[@b66-dhps-1-047],[@b87-dhps-1-047],[@b89-dhps-1-047],[@b92-dhps-1-047] In these analyses, the use of COX-2s was associated with non-significant trends toward an increased RR of POBs (RR 2.66; 95% CI 0.34 to 20.95) and PUBs (RR 2.26; 95% CI 0.96 to 5.33) ([Figure 9](#f9-dhps-1-047){ref-type="fig"}). These findings are supported by the APPROVe polyp prevention study which demonstrated that over a 3-year period, rofecoxib was associated with a statistically significant 4.9-fold increased risk of clinical ulcer complications compared to placebo.[@b9-dhps-1-047] This study was not included in the main results since its population did not include arthritis patients.

### Influence of acetylsalicylic acid co-administration on clinically important ulcer complications

Five trials allowed assessment of the effects of the co-administration of ASA with a COX-2.[@b65-dhps-1-047],[@b82-dhps-1-047],[@b91-dhps-1-047],[@b114-dhps-1-047],[@b116-dhps-1-047] In a pooled subgroup analysis of over 18,000 patients taking ASA, there was no statistically significant difference in the relative risk of ulcer complications (POBs) between those in the COX-2 arms and those in the non-selective arms of these trials (RR 0.93; 95% CI 0.68 to 1.27 for POBs). A small advantage of COX-2s over tNSAIDs cannot be ruled out by these results because this subgroup analysis might be under-powered The PUB analysis showed a statistically significant benefit for COX-2 + ASA vs tNSAID +ASA (RR 0.72; 95% CI 0.62 to 0.95), but data from one study could not be used in this analysis. In more than 40,000 patients in the COX-2 arms, patients taking ASA had a 3.46 (95% CI 2.44 to 4.91) greater relative risk of POBs than COX-2 users not taking ASA. Among 34,000 patients in the tNSAID arms of these studies, those taking ASA had a 1.65 greater relative risk of POBs than those not taking ASA, although this result did not reach statistical significance (95% CI 0.76 to 3.57). One must keep in mind that these are post-hoc subgroup analyses that might be subject to bias. Furthermore, the subgroup analysis within an tNSAID treatment group (eg, COX-2 vs COX-2 + ASA) represents a nonrandomized comparison in which differences could be influenced by factors other than ASA use ([Figures 11](#f11-dhps-1-047){ref-type="fig"} to [13](#f13-dhps-1-047){ref-type="fig"}).

### Addition of a PPI to COX-2s

The comparative safety of a COX-2s compared to a tNSAID with a PPI has been addressed in high-risk patients with recent ulcer bleeding who were enrolled after ulcer healing and *H. pylori* eradication. Chan et al[@b118-dhps-1-047] found recurrent ulcer bleeding at 6 months to be 4.9% with celecoxib 200 mg twice daily and 6.4% with diclofenac 75 mg twice daily plus omeprazole 20 mg daily. Lai et al[@b119-dhps-1-047] found recurrent ulcer complications (bleeding and 1 case of severe pain) in 3.7% with celecoxib 200 mg daily and 6.3% with naproxen 750 mg daily plus lansoprazole 30 mg daily at a median follow-up of 24 weeks. These results suggest high-risk patients have high rates of recurrent bleeding even with the protective strategy of a coxib or a tNSAID + PPI.

The combination of a coxib and PPI was assessed in the same high-risk population in a subsequent 1-year study by Chan et al[@b120-dhps-1-047] Recurrent ulcer bleeding occurred in 9% with celecoxib alone vs zero with celecoxib plus twice daily esomeprazole. The MEDAL Program also demonstrated that a coxib plus PPI had significantly fewer upper GI clinical events (again, driven by a decrease in uncomplicated events) than a tNSAID plus PPI (RR 0.62, 0.45 to 0.83).[@b116-dhps-1-047]

Symptoms and treatment withdrawals
----------------------------------

Treatment withdrawals as a result of GI side effects: COX-2s vs nonselective NSAIDs.

Twenty-one studies with close to 47,000 patients assessed the effect of COX-2s on patient withdrawals due to GI symptoms.[@b61-dhps-1-047],[@b69-dhps-1-047]--[@b71-dhps-1-047],[@b79-dhps-1-047],[@b82-dhps-1-047],[@b83-dhps-1-047],[@b87-dhps-1-047]--[@b90-dhps-1-047],[@b95-dhps-1-047],[@b98-dhps-1-047],[@b101-dhps-1-047],[@b106-dhps-1-047],[@b109-dhps-1-047],[@b110-dhps-1-047],[@b111-dhps-1-047],[@b115-dhps-1-047],[@b121-dhps-1-047]--[@b123-dhps-1-047] Overall, compared to tNSAIDs, COX-2s were associated with a significantly lower relative risk of withdrawals due to GI side effects (RR 0.65; 95% CI 0.57 to 0.73, random effects), withdrawals due to dyspepsia (RR 0.37; 95% CI 0.18 to 0.74), and due to abdominal pain (RR 0.25; 95% CI 0.13 to 0.49). Compared to placebo, low-dose COX-2s showed no statistically significant difference for these same endpoints, while high-dose COX-2s were associated with a small but significantly increased relative risk of drop-outs due to GI side effects (RR 1.74; 95% CI 1.13 to 2.68).

### Adverse GI symptoms with COX-2s compared with non-selective NSAIDs

Twenty-eight studies with close to 60,000 patients assessed the effect of low- or high-dose COX-2s compared to tNSAIDs for treatment related overall GI side effects, dyspepsia, nausea, and abdominal pain.[@b69-dhps-1-047],[@b70-dhps-1-047],[@b75-dhps-1-047]--[@b77-dhps-1-047],[@b82-dhps-1-047],[@b86-dhps-1-047],[@b87-dhps-1-047],[@b89-dhps-1-047],[@b90-dhps-1-047],[@b96-dhps-1-047]--[@b98-dhps-1-047],[@b101-dhps-1-047],[@b104-dhps-1-047],[@b106-dhps-1-047],[@b107-dhps-1-047],[@b111-dhps-1-047],[@b112-dhps-1-047],[@b114-dhps-1-047],[@b122-dhps-1-047],[@b124-dhps-1-047] Low-dose COX-2s were associated with a lower relative risk of GI symptoms (RR 0.78; 95% CI 0.74 to 0.82); dyspepsia (RR 0.83; 95% CI 0.75 to 0.90); nausea (RR 0.72; 95% CI 0.64 to 0.82); and abdominal pain (RR 0.64; 95% CI 0.58 to 0.70). The results for high-dose COX-2s were similar.

### Adverse GI symptoms with COX-2s compared with placebo

Twenty studies with over 10,000 patients compared the occurrence of adverse GI symptoms between COX-2s and placebo. Low-dose COX-2s were associated with a slight but statistically significant increased relative risk of overall GI symptoms (RR 1.26; 95% CI 1.13 to 1.42); dyspepsia (RR 1.28; 95% CI 1.08 to 1.51); nausea (RR 1.24; 95% CI 1.01 to 1.53); and abdominal pain (RR 1.24; 95% CI 1.02 to 1.52).[@b76-dhps-1-047],[@b80-dhps-1-047],[@b86-dhps-1-047],[@b87-dhps-1-047],[@b89-dhps-1-047],[@b90-dhps-1-047],[@b94-dhps-1-047],[@b96-dhps-1-047],[@b97-dhps-1-047],[@b99-dhps-1-047],[@b100-dhps-1-047],[@b104-dhps-1-047],[@b106-dhps-1-047]--[@b108-dhps-1-047],[@b122-dhps-1-047],[@b123-dhps-1-047]--[@b126-dhps-1-047] The results for high-dose COX-2s were similar.

Discussion
==========

The results of this systematic review demonstrate that there are several therapeutic strategies available to reduce the incidence of tNSAID related upper GI harms. Large, well powered, studies have shown that strategies using a tNSAID with misoprostol, or the use of a COX-2 instead of a tNSAID, each reduce the incidence of endoscopically detected upper GI ulcerations, and clinically important upper GI events such as bleeding. Misoprostol in doses that prevent upper GI ulcer complications is associated with important adverse effects which may limit its long-term use. Standard doses of H2RAs reduce the incidence of duodenal ulcers but are not effective at reducing the incidence of gastric ulcers. Double doses of H2RAs and standard-dose PPIs reduce the incidence of duodenal as well as gastric ulcers, but because tachyphylaxis can occur with chronic H2RA use, a standard-dose PPI strategy is preferred. H2RAs and PPIs have not been directly assessed in large primary prevention clinical outcome studies powered to detect ulcer complications. However, in secondary prevention studies of high-risk GI patients, tNSAIDs with a PPI appear as effective as a COX-2 strategy at preventing clinical ulcer complications. In these high-risk patients, these strategies were still associated with important ulcer relapse rates, suggesting that both strategies may provide incomplete protection for the secondary prevention of tNSAID-related ulcers. However, a recent study has shown that a strategy of combining a PPI with a COX-2 was superior to a COX-2 alone for the secondary prevention of ulcer complications, suggesting that a COX-2 + PPI strategy is the preferred strategy in high-risk GI patients. Further, the current meta-analysis, supported by the APPROVe polyp prevention study,[@b9-dhps-1-047] has shown that while COX-2 offer greater GI safety than tNSAIDs as a group, COX-2 are associated with a statistically greater risk of clinical upper GI complications than those taking placebo.

The discovery that COX-2s are associated with important cardiovascular harm has complicated the clinical use of NSAIDs significantly. Further, in Canada, all COX-2 save celecoxib have been withdrawn from the market due to cardiovascular and other harms and it is unlikely that a new COX-2 would be released to market unless it is truly cardiovascularly neutral or it is combined with a GI-safe antithrombotic agent. During this time of uncertainty, when physicians were actively switching patients back to tNSAIDs + a gastropropective agent such as a PPI, it became increasingly clear that non-naproxen tNSAIDs were also associated with important CVS harms.[@b11-dhps-1-047] A meta-analysis by Kearney et al using an extensive set of RCT data derived from published and unpublished studies has suggested that, as a group, COX-2s are associated with an increased risk of CV outcomes when compared with placebo or naproxen, but not when compared with non-naproxen, non-ASA tNSAIDs[@b11-dhps-1-047] suggesting that non-naproxen-tNSAIDs share the cardiovascular harms of COX-2s.

In light of the cardiovascular harm data relating to COX-2s, it is tempting to suggest combining these agents with ASA. However, the available data from this meta-analysis suggest that this strategy would likely undermine the GI safety advantage of COX-2s. In patients taking ASA, we found no statistically significant difference in POBs or PUBs in patients randomized to a COX-2 or a tNSAID; however, the analyses did not stratify the randomization for ASA use. Thus, it is possible that other patient-related factors played a role in this result. Furthermore, although the analysis included about 7000 patients, it is still possible that a protective effect of COX-2s over tNSAIDs in this setting is present but not detected because of insufficient statistical power. We also found that the addition of ASA to a COX-2 significantly increased the risk of a POB 4.12-times over a COX-2 alone, and that the addition of ASA to a tNSAID demonstrated a nonsignificant 1.27 increased risk of POBs over the use of a tNSAID alone. One needs to note that these analyses represent nonrandomized comparisons, and that the group sizes were somewhat uneven (more patients in the COX-2 or tNSAID alone groups than in the groups with ASA). Nonetheless, the results are not entirely unexpected, because it has been known for some time that concomitant use of multiple NSAIDs increases the risk of GI complications over a single NSAID alone. These results are also in keeping with an RCT by Laine et al[@b127-dhps-1-047] revealing that the incidence of endoscopically detected ulcers with rofecoxib and low-dose ASA was not lower than that seen with ibuprofen alone. However, it is clear that further study in this area is required to verify the above findings, such as through a dedicated RCT or from individual patient data systematic reviews. Further, adding ASA to a COX-2 implies that the COX-2s will not interfere with the effect of ASA. However, this hypothesis also requires further study because there are suggestions that the use of a tNSAID might interfere with the action of ASA in this setting, although there appears to be less interference with selective COX-2s.[@b128-dhps-1-047]--[@b132-dhps-1-047]

When COX-2s were released, they promised an era of improved GI safety, as well as an era of greater clinical simplicity, with the option of prescribing a single low risk agent when chronic NSAID use was required. However, with the greater understanding of the GI, cardiovascular, and other end organ safety profile of tNSAIDs and COX-2s, clinicians must now stratify their patients on the basis of GI, cardiovascular, and other organ system risk factors and choose an NSAID strategy, that minimizes a patient's overall risk. This has become especially difficult, for patients who are know to be at high risk of GI and cardiovascular harms.

When considering the treatment of an arthritic patient with a tNSAID or a COX-2, a clinician must consider the patient's underlying GI, cardiovascular, and other organ risks factors. Further, low-dose ASA is recommended for patients at increased cardiovascular risk;[@b133-dhps-1-047],[@b134-dhps-1-047] therefore an algorithm considering-high cardiovascular risk patients needs to assume the use of low-dose ASA in such patients. The recent Canadian Consensus Conference on NSAIDs proposed the following recommendations;[@b135-dhps-1-047] For patients with both low GI and cardiovascular risk, a tNSAID alone may be acceptable. For patients with low GI risk and high cardiovascular risk, naproxen may be preferred because of the potential lower cardiovascular risk than with other tNSAIDs or COX-2s. However, since these patients are assumed to be on low-dose ASA therapy, the combination of naproxen plus ASA would increase the GI risk, and therefore, the addition of a gastro-protective agent such as a PPI should be considered.

Long-term NSAID therapy can be more complex in patients with high GI risk. Testing for and eradicating *Helicobacter pylori* in patients at high risk of NSAID-related GI bleeding should be considered but will be insufficient without ongoing gastroprotection.[@b57-dhps-1-047],[@b136-dhps-1-047]--[@b139-dhps-1-047] In these patients, if cardiovascular risk is low, a COX-2 alone or a tNSAID with a PPI appear to offer similar protection from recurrent GI bleeding, but this protection is incomplete. Therefore, for patients at very high risk of upper GI events, a combination of a COX-2 plus a PPI may offer the best GI safety profile. When both GI and cardiovascular risks are high, the optimal strategy is to avoid NSAID therapy if at all possible. If the NSAID therapy is deemed necessary, then the clinician must prioritize the cardiovascular and GI risks, recognizing that these patients are likely taking ASA for their cardiovascular risk. If GI risk is the primary concern (ie, a very high-risk GI patient), a COX-2 plus a PPI is recommended. If the primary concern is cardiovascular risk, naproxen plus a PPI in patients on ASA would be preferred; however, GI risk should be closely monitored, as this strategy carries a higher GI risk than a COX-2 plus a PPI in patients on ASA.[@b135-dhps-1-047]
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![H2RAs compared to placebo for the prevention of gastric ulcer. Analysis by dose in studies of 12 weeks or longer duration.](dhps-1-047f3){#f3-dhps-1-047}

![H2RAs compared to placebo for the prevention of duodenal ulcer. Analysis by dose in studies of 12 weeks or longer duration.](dhps-1-047f4){#f4-dhps-1-047}

![Proton pump inhibitors compared to placebo for the prevention of gastric ulcer in studies of 8 weeks or longer duration.](dhps-1-047f5){#f5-dhps-1-047}

![Proton pump inhibitors compared to placebo for the prevention of duodenal ulcer in studies of 8 weeks or longer duration.](dhps-1-047f6){#f6-dhps-1-047}

![COX-2 vs tNSAID for endoscopic ulcers with any COX-2 dose.](dhps-1-047f7){#f7-dhps-1-047}

![Gastroduodenal ulcers analysed by individual COX-2 inhibitor compared to tNSAIDs.](dhps-1-047f8){#f8-dhps-1-047}

![POBs (perforation, obstruction or bleeding) with COX-2s vs tNSAIDs.](dhps-1-047f9){#f9-dhps-1-047}

![PUBs (POBs \[perforation, obstruction or bleeding\] or symptomatic ulcer) with COX-2s vs tNSAIDs.](dhps-1-047f10){#f10-dhps-1-047}

![Clinical ulcers (PUBs \[perforation, obstruction, bleeding or the presence of a symptomatic ulcer\]) with COX-2 + ASA vs tNSAID + ASA.\
**Note:** This is a non-randomized comparison.](dhps-1-047f11){#f11-dhps-1-047}

![Clinical ulcers (PUBs \[perforation, obstruction, bleeding or the presence of a symptomatic ulcer\]) with COX-2 + ASA vs COX-2 alone.\
**Note:** This is a non-randomized comparison.](dhps-1-047f12){#f12-dhps-1-047}

![Clinical ulcers (PUBs \[perforation, obstruction, bleeding or the presence of a symptomatic ulcer\]) with tNSAID + ASA vs tNSAID alone.\
**Note:** This is a non-randomized comparison.](dhps-1-047f13){#f13-dhps-1-047}

###### 

Included studies of gastro-protection

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                          **Comparisons**                       **NSAID**                **Number**                           **Mean age**   **Primary or secondary**    **Follow-up times (months)**   
  ---------------------------------- ------------------------------------- ------------------------ ------------------------------------ -------------- --------------------------- ------------------------------ ----------
  **Misoprostol**                                                                                                                                                                                                  

  Graham[@b30-dhps-1-047]            misoprostol 400 μg/day\               placebo                  ibuprofen, piroxicam, naproxen       421            59                          primary                        1, 2, 3
                                     misoprostol 800 μg/day                                                                                                                                                        

  Agrawal[@b21-dhps-1-047]           misoprostol 800 μg/day                placebo                  various                              356            60                          primary                        3

  Chandrasekaran[@b26-dhps-1-047]    misoprostol 600 μg/day                placebo                  various                              90             39                          primary                        1

  Saggioro[@b39-dhps-1-047]          misoprostol 800 μg/day                placebo                  various                              166            56                          primary                        1

  Bolten[@b24-dhps-1-047]            misoprostol 400--600 μg/day           placebo                  diclofenac                           361            60                          primary                        1

  Verdickt[@b42-dhps-1-047]          misoprostol 400--600 μg/day           placebo                  diclofenac                           339            53                          primary                        3

  Melo[@b14-dhps-1-047]              misoprostol 400 μg/day + diclofenac   placebo + piroxicam      piroxicam                            643            60                          primary                        1

  Graham[@b31-dhps-1-047]            misoprostol 800                       placebo                  various                              643            59                          primary                        3

  Henriksson[@b34-dhps-1-047]        misoprostol 600 μg/day                placebo                  naproxen, ibuprofen, aspirin         40             60                          primary                        1

  Roth[@b38-dhps-1-047]              misoprostol 800                       placebo                  ibuprofen                            113            53 and 60                   primary                        3

  Delmas[@b28-dhps-1-047]            misoprostol 400 μg/day\               placebo                  various                              256            54                          primary                        1
                                     misoprostol 800 μg/day                                                                                                                                                        

  Elliott[@b29-dhps-1-047]           misoprostol 600--800 μg/day           placebo                  various                              83             65                          primary                        3, 6, 12

  Agrawal[@b22-dhps-1-047]           misoprostol 400--600 μg/day           placebo                  diclofenac                           384            57                          secondary                      3, 6, 12

  Raskin[@b36-dhps-1-047]            misoprostol 400 μg/day\               placebo                  various                              1618           58                          primary                        3
                                     misoprostol 600 μg/day\                                                                                                                                                       
                                     misoprostol 800 μg/day                                                                                                                                                        

  Silverstein[@b40-dhps-1-047]       misoprostol 800 μg/day                placebo                  various                              8843           68                          primary                        24

  Bocanegra[@b23-dhps-1-047]         misoprostol 200 μg bid\               placebo                  diclofenac                           481            62                          primary                        1
                                     misoprostol 200 μg tid                                                                                                                                                        

  Chan[@b25-dhps-1-047]              misoprostol 200 bid                   nabumetone               naproxen                             90             74                          secondary                      6

  **H2 antagonists**                                                                                                                                                                                               

  Berkowitz[@b43-dhps-1-047]         ranitidine 150 mg bid                 placebo                  aspirin                              50             28.5                        primary                        1

  Roth[@b140-dhps-1-047]             cimetidine 400 mg/day                 placebo                  various                              26             nd                          primary                        10

  Ehsanullah[@b44-dhps-1-047]        ranitidine 150 mg bid                 placebo                  various                              297            57                          primary                        1, 2

  Robinson[@b46-dhps-1-047]          ranitidine 150 mg bid                 placebo                  various                              144            48                          primary                        1, 2

  Swift[@b50-dhps-1-047]             ranitidine 150 mg bid                 placebo                  various                              24             56.5                        primary                        4

  Robinson[@b45-dhps-1-047]          ranitidine 150 mg/day                 placebo                                                       227            54.2                        primary                        1

  Levine[@b49-dhps-1-047]            nizatidine 150 mg bid                 placebo                                                       496            56.9                        primary                        3

  Simon[@b51-dhps-1-047]             nizatidine 150 mg/day                 nizatidine 150 mg bid                                         237            58                          secondary                      3, 6

  Taha[@b47-dhps-1-047]              famotidine 20 mg/day\                 \                        \                                    \              \                           primary                        1, 3, 6
                                     famotidine 40 mg/day                  placebo                  various                              285            53.4                                                       

  Wolde[@b53-dhps-1-047]             ranitidine 300 bid                    placebo                                                       30             67 ranitidine, 58 placebo   secondary                      12

  Van Groenendael[@b48-dhps-1-047]   ranitidine 150 mg bid (Grp B)         placebo                  various                              36             52                          primary                        1

  Hudson[@b52-dhps-1-047]            famotidine 40 mg bid                  placebo                  various                              78             58                          secondary                      1, 3, 6

  **Proton pump inhibitors**                                                                                                                                                                                       

  Cullen[@b55-dhps-1-047]            omeprazole 20 mg/day                  placebo                                                       168                                        primary                        6

  Ekstrom[@b56-dhps-1-047]           omeprazole 20 mg/day                  placebo                  Various                              177            58                          primary                        3

  Hawkey[@b85-dhps-1-047]            misoprostol 400 μg/day\               placebo                  diclofenac, ketoprofen, naproxen     725            58                          secondary                      6
                                     omeprazole 20 mg/day                                                                                                                                                          

  Bianchi Porro[@b54-dhps-1-047]     pantoprazole 40 mg/day                placebo                  various                              104            58                          primary                        3

  Lai[@b57-dhps-1-047]               lansoprazole 30 mg                    placebo                  naproxen                             43             69                          secondary                      2

  **Head to head comparisons**                                                                                                                                                                                     

  Valentini[@b41-dhps-1-047]         misoprostol 400\                                               diclofenac                           61             59.2                        44%                            n/a
                                     ranitidine 150 mg bid                                                                                                                                                         

  Raskin[@b37-dhps-1-047]            misoprostol 800 μg/day                ranitidine 150 mg bid    various                              538            61                          primary                        2

  Hawkey[@b85-dhps-1-047]            misoprostol 400 μg/day\               placebo                  diclofenac, ketoprofen, naproxen     725            58                          secondary                      6
                                     omeprazole 20 mg/day                                                                                                                                                          

  Yeomans[@b58-dhps-1-047]           omeprazole 20 mg/day                  ranitidine 150 mg bid    diclofenac, indomethacin, naproxen   425            56                          30%                            1, 2

  Jensen[@b35-dhps-1-047]            misoprostol 200 μg qid                omeprazole 20 mg bid     various                              46             n/a                         secondary                      6

  Graham[@b32-dhps-1-047]            misoprostol 800 μg\                   placebo                  various                              537            60                          secondary                      3
                                     lansoprazole 15 mg\                                                                                                                                                           
                                     lansoprazole 30 mg                                                                                                                                                            

  Stupnicki[@b13-dhps-1-047]         misoprostol 400 μg/day                pantoprazole 40 mg/day   diclofenac                           515            55                          primary                        1
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

COX-2 included studies

  **Endpoint**                                         **Study**                                                                                 **Comparisons**                                                            **Number of patients**   **Mean age**   **Arthritis type**   **Follow-up**                  
  ---------------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------ -------------- -------------------- ------------------------------ --
  **Endoscopic ulcer**                                 **Celecoxib**                                                                                                                                                                                                                                                    
  Emery[@b70-dhps-1-047]                               200 mg bid                                                                                diclofenac 75 mg bid                                                       655                      55             RA                   24 weeks                       
  FDA, 021                                             50 mg bid, 100 mg bid, 200 mg bid                                                         naproxen 500 mg bid; placebo                                               1,108                    unk            OA                   2, 6, 12 weeks                 
  FDA, 071                                             200 mg bid                                                                                diclofenac 75 mg bid; ibuprofen 800 mg tid                                 1,097                    unk            OA and RA            4, 8, 12 weeks                 
  Goldstein[@b69-dhps-1-047]                           200 mg bid                                                                                naproxen 500 mg bid                                                        537                      57             OA and RA            4, 8, 12 weeks                 
  Simon[@b71-dhps-1-047]                               100 mg bid, 200 mg bid, 400 mg bid                                                        naproxen 500 mg bid; placebo                                               1,149                    54             RA                   2, 6, 12 weeks                 
  **Rofecoxib**                                                                                                                                                                                                                                                                                                         
  Hawkey[@b73-dhps-1-047]                              25 mg/day, 50 mg day                                                                      ibuprofen 800 mg tid                                                       775                      62             OA                   6 weeks, 3, 6 months           
  Hawkey[@b74-dhps-1-047]                              50 mg/day                                                                                 naproxen 500 mg bid; placebo                                               660                      51.7           RA                   3, 6, 9, 12 weeks              
  Laine[@b72-dhps-1-047]                               25 mg/day, 50 mg/day                                                                      ibuprofen 800 mg tid                                                       742                      62             OA                   6 weeks, 3, 6 months           
  **Etoricoxib**                                                                                                                                                                                                                                                                                                        
  Hunt[@b78-dhps-1-047] -- multiple                    120 mg/day                                                                                ibuprofen 800 mg tid                                                       680                      62             OA                   3, 6, 9, 12 weeks              
  Hunt[@b79-dhps-1-047] -- naproxen                    120 mg/day                                                                                naproxen 500 mg bid; placebo                                               742                      54             OA and RA            3, 6, 9, 12 weeks              
  **Valdecoxib**                                                                                                                                                                                                                                                                                                        
  FDA 047                                              20 mg bid, 40 mg bid                                                                      naproxen 500 mg bid                                                        1,217                    56             OA and RA            26 weeks                       
  FDA 063                                              10 mg/day, 20 mg/day                                                                      diclofenac 75 mg bid                                                       784                      unk            OA                   1, 2, 4, 6 weeks               
  Kivitz[@b80-dhps-1-047]                              5 mg/day, 10 mg/day, 20 mg/day                                                            naproxen 500 mg tid; placebo                                               1,019                    60             OA                   2, 6, 12 weeks                 
  Sikes[@b76-dhps-1-047]                               10 mg/day, 20 mg/day                                                                      ibuprofen 800 mg tid; diclofenac 75 mg bid; placebo                        1,052                    60             OA                   2, 6, 12 weeks                 
  **Lumiracoxib**                                                                                                                                                                                                                                                                                                       
  Hawkey[@b74-dhps-1-047],[@b113-dhps-1-047]           lumiracoxib 200 mg/day, 400 mg/day; celecoxib 200 mg/day                                  ibuprofen 800 mg tid                                                       1,042                    58.7           OA                   4, 8, 13 weeks                 
  Kivitz[@b81-dhps-1-047]                              lumiracoxib 400 mg/day, 800 mg/day; celecoxib 200 mg bid                                  ibuprofen 800 mg tid                                                       893                      51.7           RA                   8, 13 weeks                    
  **Clinical ulcer complications**                     **Celecoxib**                                                                                                                                                                                                                                                    
  Goldstein[@b92-dhps-1-047] combined analysis study   25 mg bid to 400 mg bid                                                                   naproxen 500 mg bid; diclofenac 75 mg bid; ibuprofen 800 mg tid; placebo   11,008                   59             OA and RA            2 to 24 weeks                  
  Silverstein[@b82-dhps-1-047]                         400 mg bid                                                                                diclofenac 75 mg bid; iboprofen 800 mg tid                                 8,059                    60             OA and RA            4, 13, 26 weeks (1 year FDA)   
  Singh[@b91-dhps-1-047] Success-1                     100 mg bid, 200 mg bid                                                                    naproxen 500 mg bid                                                        13,274                   62             OA                   6, 12 weeks                    
  Zhao[@b89-dhps-1-047]                                50 mg bid, 100 mg bid, 200 mg bid                                                         naproxen 500 mg bid: placebo                                               1,004                    62.2           OA                   2, 6, 12 weeks                 
  **Rofecoxib**                                                                                                                                                                                                                                                                                                         
  Bombardier[@b83-dhps-1-047]                          50 mg/day                                                                                 naproxen 500 mg bid                                                        8,076                    58             RA                   4, 8, 12 months                
  Geusens[@b90-dhps-1-047]                             25 mg/day, 50 mg/day                                                                      naproxen 500 mg bid; placebo                                               1,023                    53.6           RA                   2, 4, 8, 12 weeks              
  Langman[@b66-dhps-1-047] combined analysis study     25 mg/day, 50 mg/day                                                                      ibuprofen 800 mg tid; diclofenac 50 mg tid; nabumetone 1,500 mg/day        5,435                    63             OA                   6 weeks, 4, 6, 12, 24 months   
  Lisse[@b88-dhps-1-047]                               25 mg/day                                                                                 naproxen 500 mg bid                                                        5,597                    63             OA                   3, 6, 9, 12 weeks              
  Saag[@b101-dhps-1-047]                               12.5 mg/day, 25 mg/day                                                                    ibuprofen 800 mg tid                                                       736                      61             OA                   2, 4, 6 weeks                  
  Saag[@b101-dhps-1-047]                               12.5 mg/day, 25 mg/day                                                                    diclofenac 50 mg tid                                                       693                      62             OA                   up to 1 year                   
  **Etoricoxib**                                                                                                                                                                                                                                                                                                        
  Leung[@b87-dhps-1-047]                               60 mg/day                                                                                 naproxen 500 mg bid; placebo                                               501                      63             OA                   2, 4, 8, 12 weeks              
  Ramey[@b68-dhps-1-047] combined analysis study       5 to 120 mg/day                                                                           diclofenac 150 mg/day; naproxen 1000 mg/day; ibuprofen 2400 mg/day         5,441                    56.7           OA and RA            up to 190 weeks                
  Laine[@b116-dhps-1-047] MEDAL                        60 or 90 mg/day                                                                           diclofenac 150 mg/day                                                      34 701                   63             OA and RA            up to 36 months                
  **Valdecoxib**                                                                                                                                                                                                                                                                                                        
  Goldstein[@b92-dhps-1-047] combined analysis study   5 to 80 mg/day                                                                            naproxen 500 mg bid; diclofenac 75 mg bid; ibuprofen 800 mg tid; placebo   7,445                    58.1           OA and RA            up to 26 weeks                 
  **Lumiracoxib**                                                                                                                                                                                                                                                                                                       
  Schnitzer[@b86-dhps-1-047] TARGET                    400 mg/day                                                                                naproxen 500 mg bid; ibuprofen 800 mg tid                                  18,244                   63.5           OA                   4, 13, 20, 26, 39, 52 weeks    
  **COX-2 and PPI**                                                                                                                                                                                                                                                                                                     
  Chan[@b118-dhps-1-047]                               celecoxib 200 mg bid                                                                      diclofenac 75 mg + omeprazole 20 mg                                        287                      67             OA and RA            24 weeks                       
  Lai[@b119-dhps-1-047]                                celecoxib 200 mg daily                                                                    naproxen 250 mg tid + lansoprosol 30 mg                                    142                      57             OA and RA            24 weeks                       
  Chan[@b120-dhps-1-047]                               celecoxib 200 mg bid                                                                      celecoxib 200 mg bid; esomeprazole 20 mg bid                               271                      71             OA and RA            52 weeks                       
  **Tolerability**                                     **Celecoxib**                                                                                                                                                                                                                                                    
  Bensen[@b95-dhps-1-047]                              50 mg bid, 100 mg bid, 200 mg bid                                                         naproxen 500 mg bid; placebo                                               1,003                    62             OA                   2, 6, 12 weeks                 
  Geba[@b102-dhps-1-047]                               celecoxib 200 mg/day; rofecoxib 12.5 mg/day, 25 mg/day                                    acetaminophen 4000 mg/day                                                  382                      63             OA                   2, 4, 6 weeks                  
  Kivitz[@b122-dhps-1-047]                             100 mg/day, 200 mg/day, 400 mg/day                                                        naproxen 500 mg bid; placebo                                               1,061                    62.6           OA                   2, 6, 12 weeks                 
  McKenna[@b104-dhps-1-047]                            100 mg bid                                                                                diclofenac 50 mg tid; placebo                                              600                      62             OA                   2, 6 weeks                     
  McKenna[@b105-dhps-1-047]                            celecoxib 200 mg/day; rofecoxib 25 mg/day                                                 placebo                                                                    182                      62             OA                   3, 6 weeks                     
  Whelton[@b103-dhps-1-047]                            celecoxib 200 mg/day; rofecoxib 25 mg/day                                                 none                                                                       811                      74             OA                   1, 2, 6 weeks                  
  Williams[@b94-dhps-1-047]                            200 mg/day                                                                                placebo                                                                    686                      63             OA                   2, 6 weeks                     
  Williams[@b142-dhps-1-047]                           100 mg bid, 200 mg/day                                                                    placebo                                                                    718                      61.5           OA                   2, 6 weeks                     
  **Rofecoxib**                                                                                                                                                                                                                                                                                                         
  Cannon[@b98-dhps-1-047]                              12.5 mg/day 25 mg/day                                                                     diclofenac 50 mg tid                                                       784                      64             OA                   up to 1 year                   
  Day[@b97-dhps-1-047]                                 12.5 mg/day, 25 mg/day                                                                    ibuprofen 800 mg tid                                                       809                      64             OA                   2, 4, 6 weeks                  
  Ehrich[@b99-dhps-1-047]                              25 to 125 mg/day                                                                          placebo                                                                    219                      64             OA                   1, 2, 4, 6 weeks               
  Myllykangas[@b121-dhps-1-047]                        12.5 mg/day                                                                               naproxen 500 mg bid                                                        944                      61.6           OA                   2, 4, 6 weeks                  
  Schnitzer[@b100-dhps-1-047]                          5 to 50 mg/day                                                                            placebo                                                                    658                      55             RA                   2, 4, 8 weeks                  
  Truitt[@b96-dhps-1-047]                              12.5 mg/day, 25 mg/day                                                                    nabumetone 1500 mg/day; placebo                                            341                      83             OA                   1, 2, 4, 6 weeks               
  **Etoricoxib**                                                                                                                                                                                                                                                                                                        
  Collantes[@b110-dhps-1-047]                          90 mg/day                                                                                 naproxen 500 mg bid; placebo                                               891                      52             RA                   2, 4, 8, 12 weeks              
  Gottesdiener[@b108-dhps-1-047]                       Part 1: 5 to 90 mg/day Part 2: 30 mg/day, 60 mg/day 90 mg/day                             Part 1: placebo Part 2: diclofenac 50 mg tid                               617                      60             OA                   1, 2, 4, 6, 8, 14 weeks        
  Matsumoto[@b111-dhps-1-047]                          90 mg/day                                                                                 naproxen 500 mg bid; placebo                                               816                      56             RA                   2, 4, 8, 12 weeks              
  Wiesenhutter[@b123-dhps-1-047]                       30 mg/day                                                                                 ibuprofen 2400 mg/day; placebo                                             258                      61.3           OA                   1, 2, 4, 6 weeks               
  Zacher[@b109-dhps-1-047]                             60 mg/day                                                                                 diclofenac 50 mg tid                                                       516                      63             OA                   2, 4, 6, 8 weeks               
  **Valdecoxib**                                                                                                                                                                                                                                                                                                        
  Bensen[@b107-dhps-1-047]                             10 mg/day, 20 mg/day, 40 mg/day                                                           naproxen 500 mg bid; placebo                                               1,090                    55             RA                   4, 8, 12 months                
  FDA 061                                              10 mg/day, 20 mg/day, 40 mg/day                                                           naproxen 500 mg bid; placebo                                               1,093                    57             RA                   12 weeks                       
  Makarowski[@b106-dhps-1-047]                         5 mg/day, 10 mg/day                                                                       naproxen 500 mg bid; placebo                                               513                      68             OA                   3 weeks                        
  Pavelka[@b77-dhps-1-047]                             20 mg/day, 40 mg/day                                                                      diclofenac 75 mg bid                                                       722                      56             RA                   2, 6, 8, 12, 18, 26 weeks      
  **Lumiracoxib**                                                                                                                                                                                                                                                                                                       
  Geusens[@b124-dhps-1-047]                            200 mg/day, 400 mg/day                                                                    naproxen 500 mg bid                                                        1,124                    71             RA                   2, 4, 13, 20, 26 weeks         
  Grifka[@b125-dhps-1-047]                             200 mg/day, 400 mg/day                                                                    placebo                                                                    594                      61.9           OA                   2, 4, 6 weeks                  
  Lehmann[@b126-dhps-1-047]                            100 mg/day, 100 mg/day with 200 mg loading dose for first 2 weeks; celecoxib 200 mg/day   placebo                                                                    1,684                    62.4           OA                   2, 4, 8, 13 weeks              
  Schnitzer[@b86-dhps-1-047]                           50 mg bid, 100 mg bid, 200 mg bid, 400 mg bid                                             diclofenac 400 mg bid; placebo                                             583                      60.3           OA                   4 weeks                        
  Schnitzer[@b86-dhps-1-047]                           50 mg bid, 100 mg bid, 200 mg bid, 400 mg bid                                             diclofenac 400 mg bid; placebo                                             569                      54.4           RA                   2, 6, 12 weeks                 
  Tannenbaum[@b141-dhps-1-047]                         lumiracoxib 200 mg/day, 400 mg/day; celecoxib 200 mg/day                                  placebo                                                                    1,702                    64.3           OA                   2, 4, 8, 13 weeks              

**Abbreviations:** unk, unknown; OA, osteoarthritis; PPI, protein pump inhibitors; RA, rheumatoid arthritis.
